LENZ
LENZ Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.04 / 10
Netural
Fund flow evaluation: 7.87/10 reflecting robust fund flow characteristics. Constructive overall, block, Small, Large, and Extra-large trends face headwinds from adverse Medium developments, indicating positive money flow direction. Professional analyst opinion suggests overwhelmingly bullish analyst consensus, showing strong conviction. Distribution pattern: Buy(100.0%) based on 2 research evaluations, supported by 2.20 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-10
InstitutionPiper Sandler
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of LENZ?
- LENZ holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.04/10 (Netural).
